Table 2. Clinical characteristics (n = 4).
| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Onset of DFR (treatment duration of dupilumab, wk) | 27 | 25 | 20 | 17 |
| Signs and symptom of facial redness (+/−) erythema/scale/itching/pain | +/+/−/− | +/+/−/− | +/+/−/− | +/−/−/− |
| Skin biopsy (+/−) | − | − | + | − |
| Patch test (+/−) | + | − | − | − |
| Concomitant treatment | Emollients, TCS, TCI, antihistamine | Emollients, TCS, TCI, prednisone, antihistamine | Emollients, TCS, TCI | Emollients, TCS, TCI, antihistamine |
| Prescriptions for DFR | Minocycline, TCI, brimonidine tartrate 0.33% topical gel | Minocycline, TCI, TCS | Minocycline, TCI, TCS, brimonidine tartrate 0.33% topical gel | Minocycline, TCI, TCS |
| Duration of treatment for DFR (wk) | 28 | 10 | 22 | 32 |
DFR, dupilumab facial redness; TCS, topical corticosteroids; TCI, topical calcineurin inhibitors.